Volume 135, Issue 5, Pages 1561-1567 (November 2008) Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy  Peter Ferenci, Thomas–Matthias Scherzer, Heidrun Kerschner, Karoline Rutter, Sandra Beinhardt, Harald Hofer, Maximilian Schöniger– Hekele, Heidemarie Holzmann, Petra Steindl–Munda  Gastroenterology  Volume 135, Issue 5, Pages 1561-1567 (November 2008) DOI: 10.1053/j.gastro.2008.07.072 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Study 1: Parameters of oxidative stress during and after infusion of 10 mg/kg silibinin over 4 hours. (d-ROMs test, reactive oxygen metabolites-derived compounds; BAP test, biological antioxidant potential. Gastroenterology 2008 135, 1561-1567DOI: (10.1053/j.gastro.2008.07.072) Copyright © 2008 AGA Institute Terms and Conditions

Figure 2 Study 1: HCV RNA (log IU/mL; mean ± SD) before (day 1) and after 7 days of IV 10 mg silibinin/kg/day. Gastroenterology 2008 135, 1561-1567DOI: (10.1053/j.gastro.2008.07.072) Copyright © 2008 AGA Institute Terms and Conditions

Figure 3 Study 1: Changes in HCV RNA after IV administration of 10 mg/kg/day silibinin for 7 days, followed by combination therapy with PegIFNα-2a/RBV and 140 mg silymarin 3 times daily. Gastroenterology 2008 135, 1561-1567DOI: (10.1053/j.gastro.2008.07.072) Copyright © 2008 AGA Institute Terms and Conditions

Figure 4 Study 2: Changes in HCV RNA during IV administration of silibinin at various doses for 14 days, followed by combination therapy with PegIFNα-2a/RBV, which was started on day 8. Gastroenterology 2008 135, 1561-1567DOI: (10.1053/j.gastro.2008.07.072) Copyright © 2008 AGA Institute Terms and Conditions

Figure 5 Study 2: Mean (±SD) decrease of HCV RNA during 7 day IV administration of silibinin monotherapy and 7 days of IV silibinin in combination with PegIFNα-2a/RBV at various doses. Gastroenterology 2008 135, 1561-1567DOI: (10.1053/j.gastro.2008.07.072) Copyright © 2008 AGA Institute Terms and Conditions

Figure 6 Study 2: Changes in HCV RNA after the end of IV silibinin (week 2) in the 14 patients who received 15 or 20 mg/kg/silibinin/day. Combination therapy with PegIFNα-2a/RBV was started on day 8 and 280 mg silymarin 3 times daily on day 15. Data for the 5- and 10-mg/kg groups are not shown, and HCV RNA increased in all 6 patients after the end of the silibinin infusions. Gastroenterology 2008 135, 1561-1567DOI: (10.1053/j.gastro.2008.07.072) Copyright © 2008 AGA Institute Terms and Conditions